CLVS Gets FDA Nod, PBYI Leaves Big Board, LOXO Hits All-time High, CNAT On Watch

Shares of Clovis Oncology Inc. (CLVS) rose as much as 27% on Monday, following FDA's accelerated approval of the company's ovarian cancer drug Rubraca.

from RTT - Biotech http://ift.tt/2h5EaNa
via IFTTT